HI SR44

Urges the Hawaii Department of Health to coordinate stockpiling a three-year supply of mifepristone, the oral medication used in approximately 63% of abortions in the United States.

Cites concerns about potential federal changes to mifepristone administration and supply chain disruptions following the 2022 Dobbs decision overturning Roe v. Wade.

Notes the Department of Health partnered with Kapiolani Medical Center in 2023 to maintain a one-year supply; mifepristone has a five-year shelf life.

References Hawaii's constitutional protections for privacy and bodily autonomy, and its 1970 status as the first state to legalize abortion.

Highlights access disparities, as in-person abortion care is only available on Maui and Oahu, with an estimated 3,900 abortions occurring statewide in 2024.